Is Ocular Therapeutix (OCUL) Stock a Buy Ahead of Its Major NDA Catalyst?

Ocular Therapeutix (OCUL) finds itself at a critical juncture as it prepares to submit a New Drug Application (NDA) for its investigational treatment AXPAXLI, designed to treat wet age-related macular degeneration (wet AMD). The bioresorbable hydrogel delivery system, utilizing axitinib, holds the potential to transform how this chronic retinal disease is managed.

A key advantage lies in its ability to significantly reduce the frequency of injections required, addressing a major patient adherence barrier that currently sees around 40% of wet AMD patients discontinue therapy within a year. Regulatory progress has been robust, with a pre-NDA meeting approval from the US FDA and promising clinical data from the Phase 3 SOL-1 trial demonstrating superior efficacy and reduced injection burden compared to current standards.

However, this promising path is not without challenges. The company is currently navigating substantial cash burn, with net losses widening to $78.8 million in the second quarter of 2026, and a relatively narrow revenue base primarily from its legacy product DEXTENZA. Additionally, longer-term trials are extending the timeline for definitive competitive data beyond the initial wet AMD indication, potentially delaying commercialization beyond 2027.

Market sentiment is polarized, with a notable short interest at 15.08% of the float, indicating cautious optimism. While there is strong institutional support, some analysts argue that the execution risks and dilution concerns present significant hurdles that could outpace the potential upside.